Gemcitabine as adjuvant chemotherapy in patients with high-risk early breast cancer—results from the randomized phase III SUCCESS-A trial

Gemcitabine as adjuvant chemotherapy in patients with high-risk early breast cancer—results from the randomized phase III SUCCESS-A trial

Abstract Background When chemotherapy is indicated in patients with early breast cancer, regimens that contain anthracyclines and taxanes are established standard treatments. Gemcitabine has shown promising effects on the response and prognosis in patients with metastatic breast cancer. The SUCCESS-...

Full description

Bibliographic Details
Main Authors: Amelie de Gregorio, Lothar Häberle, Peter A. Fasching, Volkmar Müller, Iris Schrader, Ralf Lorenz, Helmut Forstbauer, Thomas W. P. Friedl, Emanuel Bauer, Nikolaus de Gregorio, Miriam Deniz, Visnja Fink, Inga Bekes, Ulrich Andergassen, Andreas Schneeweiss, Hans Tesch, Sven Mahner, Sara Y. Brucker, Jens-Uwe Blohmer, Tanja N. Fehm, Georg Heinrich, Krisztian Lato, Matthias W. Beckmann, Brigitte Rack, Wolfgang Janni
Format: Article
Language:English
Published: BMC 2020-10-01
Series:Breast Cancer Research
Subjects:
Early breast cancer
Gemcitabine
Chemotherapy
Online Access:http://link.springer.com/article/10.1186/s13058-020-01348-w

Internet

http://link.springer.com/article/10.1186/s13058-020-01348-w

Similar Items